Warnings for special population
Pregnancy
Due to a lack of safety and efficacy studies in pregnant women, the risk to your developing foetus due to Ticagat Tablet is not known. This medicine is not recommended during pregnancy unless necessary. If you are pregnant, consult your doctor.
Breast-feeding
It is not known whether Ticagat Tablet passes into breastmilk. Hence this medicine is not recommended during breastfeeding unless necessary. If you are breastfeeding, consult your doctor.
General warnings
Other medicines
Ticagat Tablet may interact with other medicines and cause undesired side effects. Hence, inform your doctor about your current medicines including any herbs and supplements before beginning treatment with this medicine.
Bleeding
Ticagat Tablet may increase your risk for bleeding and should be used with caution if you had recent surgery, have a history of bleeding in your stomach/intestines, have pre-existing liver problems or if you are on treatment with certain medicines (e.g. non-steroidal anti-inflammatory drugs, oral anticoagulants, fibrinolytics) that may increase your risk of bleeding due to the increased risk of further worsening your condition.
Dyspnoea
Ticagat Tablet may increase your risk of dyspnoea (shortness of breath). This risk is especially higher if you have a history of asthma/chronic obstructive pulmonary disease (lung problems that cause breathing difficulty) and hence caution is required.
Discontinuation of treatment
Discontinuation of treatment with Ticagat Tablet may increase your risk of myocardial infarction (heart attack), stroke (damage to your brain resulting from reduced/blocked blood supply), or death. Hence it is recommended to continue using this medicine for the duration prescribed by your doctor.
Heart rhythm abnormalities
Ticagat Tablet may increase your risk of an irregular heart rhythm. This risk is especially higher if you have pre-existing heart problems and hence caution is required. Your electrocardiogram and electrolyte levels need to be closely monitored for the assessment of heart function.
Use in Children
Ticagat Tablet is not recommended for use in children below 18 years of age due to a lack of safety and efficacy studies.
Driving or Operating machines
Ticagat Tablet may cause dizziness and blurred vision. If you experience any symptoms that may affect your mental alertness, do not drive vehicles or operate machines.
Surgery
If you are on treatment with Ticagat Tablet, inform your doctor before planning surgery. Since Ticagat Tablet may increase your risk of bleeding, it is recommended to discontinue treatment with this medicine at least 5 days before undergoing surgery. However, your doctor may suggest the appropriate time of withdrawal based on your clinical condition.
Increased creatinine levels
Ticagat Tablet may cause an increase in creatinine levels. It is recommended to periodically monitor your kidney function after beginning treatment with this medicine.
Hyperuricaemia
Ticagat Tablet may increase your risk of hyperuricaemia (high blood uric acid levels). This medicine should be used with caution if you have a history of hyperuricaemia or gouty arthritis (a type of arthritis resulting from the accumulation of uric acid crystals in joint spaces).
Thrombotic thrombocytopenic purpura
Ticagat Tablet may increase your risk of thrombotic thrombocytopenic purpura, a rare condition that causes blood clots to form in small blood vessels throughout your body.